Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2013-05-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm400072pPMID 23611691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.

  2013cited by this paper
• Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.

  2013cited by this paper
• 3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen synthase kinase-3.

  2013cited by this paper
• Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

  2012cited by this paper
• ZD1839 (‘Iressa’)1,2 as an Anticancer Agent

  2012cited by this paper
• The design, synthesis, and biological evaluation of PIM kinase inhibitors.

  2012cited by this paper
• Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.

  2012cited by this paper
• Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

  2012cited by this paper
• SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

  2012cited by this paper
• Affinity-based probes based on type II kinase inhibitors.

  2012cited by this paper
• Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

  2012cited by this paper
• Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity

  2012cited by this paper
• An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.

  2012cited by this paper
• Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

  2012cited by this paper
• Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

  2012cited by this paper
• Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.

  2012cited by this paper
• Crystal structure of human CDC7 kinase in complex with its activator DBF4

  2012cited by this paper
• IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.

  2012cited by this paper
• Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.

  2012cited by this paper
• Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC

  2012cited by this paper
• Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.

  2011cited by this paper
• Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

  2011cited by this paper
• Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders

  2011cited by this paper
• Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

  2011cited by this paper
• Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.

  2010cited by this paper
• Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis

  2010cited by this paper
• Through the "gatekeeper door": exploiting the active kinase conformation.

  2010cited by this paper
• X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.

  2010cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• MolProbity: all-atom structure validation for macromolecular crystallography

  2009cited by this paper
• Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.

  2009cited by this paper
• research papers Journal of Applied

  2009cited by this paper
• Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.

  2009cited by this paper
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  2009cited by this paper
• ErbB receptors and signaling pathways in cancer.

  2009cited by this paper
• A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors.

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

  2007cited by this paper
• Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

  2007cited by this paper
• c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.

  2007cited by this paper
• Review: side effects of approved molecular targeted therapies in solid cancers.

  2007cited by this paper
• c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

  2007cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007cited by this paper
• Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.

  2007cited by this paper
• Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

  2006cited by this paper
• Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice

  2006cited by this paper
• Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.

  2005cited by this paper
• Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

  2005cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors

  2004cited by this paper
• High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• The conformational plasticity of protein kinases.

  2002cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Mistletoe for cancer?

  2001cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• Correspondence e-mail:

  2000cited by this paper
• ZD1839 ('Iressa') as an anticancer agent.

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• MOLREP: an Automated Program for Molecular Replacement

  1997cited by this paper
• Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

  1997cited by this paper
• Crystal structure of the Src family tyrosine kinase Hck

  1997cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

  1995cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution.

  1994cited by this paper
• Crystal structure of the tyrosine kinase domain of the human insulin receptor

  1994cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Optimization of Inhibitors of the Tyrosine Kinase Ephb4. 2. Cellular Potency Improvement and Binding Mode Validation by X‑ray Crystallography ■ Lead Optimization Strategy

  year unknowncited by this paper

• Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy

  2026cites this paper
• Development of a Practical and Scalable Synthetic Route for DBPR112: A Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

  2026cites this paper
• Leak Proof PDBBind: A Reorganized Data Set of Protein-Ligand Complexes for More Generalizable Binding Affinity Prediction.

  2026cites this paper
• Sonogashira-Hydroamination based Annulation of 2-(2-chloro-1-methyl-1H-indol-3-yl)-5-methyl-1H-benzo[d]imidazole: Antiproliferative Activity, DFT, and Molecular Docking Studies

  2025cites this paper
• Novel pyrido[2,3-b][1,4]oxazine-based EGFR-TK inhibitors: rational design and synthesis of potent and selective agents targeting resistance mutations in non-small cell lung cancer.

  2025cites this paper
• Exploring the Therapeutic Potential of Moringa oleifera Against Lung Cancer Through Network Modeling and Molecular Docking Analysis

  2025cites this paper
• Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions

  2025cites this paper
• Well-Tempered Metadynamics Simulations Combined with Free Energy Landscape Analysis Uncover the Conformational Transition Pathway of the DYG Motif in LRRK2.

  2025cites this paper
• FL30: an epidermal growth factor kinase inhibitor overcoming T790M and C797S mutations through unique conformational modulation mechanism.

  2025cites this paper
• Recent development of heterocyclic scaffolds as EGFR kinase inhibitors in cancer

  2025cites this paper
• Discovery of Novel Multiangiogenic Agents Targeting VEGFR2, EphB4, FGFR-1, and TIE-2: Receptor-Based Pharmacophore Modeling, Virtual Screening, and Molecular Modeling Studies

  2025cites this paper
• Chemical Inhibition of Splicing-Related Protein Kinases Reveals Phosphorylation-Driven Regulation of RNA Alternative Splicing in Arabidopsis Seedlings

  2025cites this paper
• Salicylaldehyde Benzoylhydrazones with Anticancer Activity and Selectivity: Design, Synthesis, and In Vitro Evaluation

  2025cites this paper
• A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway

  2025cites this paper
• Pyrazole derivatives as dual COX-2/EGFR inhibitors with anticancer potential: Optimization of difenamizole Analogs.

  2025cites this paper
• Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐b]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC

  2025cites this paper
• Repurposing Non‐Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M‐Mediated Acquired Resistance in Non‐Small Cell Lung Cancer

  2024cites this paper
• Covalent Epidermal Growth Factor Receptor (EGFR) Inhibitors in Targeted Therapy of Drug-Resistant Non-Small Cell Lung Cancer (A Review)

  2024cites this paper
• Cyclic Peptides as Protein Kinase Modulators and Their Involvement in the Treatment of Diverse Human Diseases

  2024cites this paper
• Recent Applications of In Silico Approaches for Studying Receptor Mutations Associated with Human Pathologies

  2024cites this paper
• In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia

  2024cites this paper
• Combination of ligand‑based and structure‑based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms

  2024cites this paper
• Novel, tightly structurally related N-myristoyltransferase inhibitors display equally potent yet distinct inhibitory mechanisms.

  2024cites this paper
• TPCA-1 compound, inhibiting testis-specific serine/threonine protein kinase 3 for potential male sterile in Bombyx mori.

  2024cites this paper
• Binding Affinity Determination in Drug Design: Insights from Lock and Key, Induced Fit, Conformational Selection, and Inhibitor Trapping Models

  2024cites this paper
• Repurposing Castanea sativa Spiny Burr By-Products Extract as a Potentially Effective Anti-Inflammatory Agent for Novel Future Biotechnological Applications

  2024cites this paper
• Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy

  2024cites this paper
• Exploring the role of TLK2 mutation in tropical calcific pancreatitis: an in silico and molecular dynamics simulation study

  2024cites this paper
• Inhibitor Trapping in Kinases

  2024cites this paper
• A Drug Discovery Approach to a Reveal Novel Antioxidant Natural Source: The Case of Chestnut Burr Biomass

  2024cites this paper
• Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer

  2024cites this paper
• Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study

  2024cites this paper
• Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro

  2023cites this paper
• A role of salt bridges in mediating drug potency: A lesson from the N-myristoyltransferase inhibitors

  2023influential citation
• Exploration of the antiproliferative and antioxidant effects and the molecular docking study EGFR and VEGFR2 of essential oil from Citrus aurantium Peels

  2023cites this paper
• Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study

  2023cites this paper
• Three compounds from banana pseudostem inhibit mitotic cell division by interacting with tubulin and cyclin-dependent kinase 2 proteins: in vivo, in vitro and in silico approach

  2023cites this paper
• Derivates of 1,6-dihyadroazaazulenes as inhibitors of tyrosine kinases BCR-ABL1 wild type and mutant T315I: a molecular dynamics approach

  2023cites this paper
• Design and Self Assembly of Tri-Terpene Peptide Conjugates and Their Interactions with EGFR and EGFR Mutant Receptors: An In Silico and In Vitro Study

  2023cites this paper
• Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion.

  2023cites this paper
• Optical Control of Protein Functions via Genetically Encoded Photocaged Aspartic Acids.

  2023cites this paper
• Leak Proof PDBBind: A Reorganized Dataset of Protein-Ligand Complexes for More Generalizable Binding Affinity Prediction

  2023cites this paper
• In silico analysis of the interaction of de novo peptides derived from Salvia hispanica with anticancer targets

  2023cites this paper
• Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.

  2023cites this paper
• Exploration of Targeted Anti-tumor Therapy

  2023cites this paper
• Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma

  2023cites this paper
• Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents

  2023cites this paper
• Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.

  2022cites this paper
• Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers.

  2022cites this paper
• Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.

  2022cites this paper
• Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations

  2022cites this paper
• A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC

  2022cites this paper
• Computational targeting of allosteric site of MEK1 by quinoline‐based molecules

  2022cites this paper
• Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay

  2022cites this paper
• Identification of Combination Drug Interaction With Selected Targets of Globlastoma Multiforme Based on Drug Properties and Complex Energy of Docked Complex: a New Approach in Docking Study

  2022cites this paper
• EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.

  2021cites this paper
• Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.

  2021cites this paper
• The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis.

  2021cites this paper
• Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.

  2021cites this paper
• Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents

  2021cites this paper
• Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug

  2021cites this paper
• Design , Synthesis and Biological Evaluation of Novel Pyrazolo [ 1 , 2 , 4 ] triazolopyrimidine Derivatives as Potential Anticancer

  2021cites this paper
• Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

  2021cites this paper
• Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach

  2021cites this paper
• Inter Molecular Level Interaction Studies of Combination Drug Crizotinib And Temozolomide in Glioblastoma Multiforme Targets: An In-silico Approach

  2021cites this paper
• The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.

  2020cites this paper
• Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2

  2020cites this paper
• Pd(II)‐catalyzed, Picolinamide‐aided sp 2 γ−C−H Functionalization of Phenylglycinol: Access to γ−C−H Arylated, Alkylated and Halogenated Phenylglycinol Scaffolds

  2020cites this paper
• Toward structure-based drug design against the epidermal growth factor receptor (EGFR)

  2020cites this paper
• Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.

  2020cites this paper
• The study of EGFR-ligand complex electron property relationship with biological activity

  2020cites this paper
• Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics.

  2020cites this paper
• Orthosteric and allosteric modulation of human kinases: A mechanistic view.

  2020cites this paper
• Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.

  2019cites this paper
• Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase

  2019cites this paper
• AlCl 3 ‐Promoted Stereospecific Cloke‐Wilson Rearrangement of Spirocyclopropyl Barbiturates for the Synthesis of Substituted Dihydrofuro[2,3‐ d ]pyrimidines

  2019cites this paper
• Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

  2019cites this paper
• Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank

  2019cites this paper
• Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors

  2019cites this paper
• Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

  2019cites this paper
• Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.

  2019cites this paper
• Current Approaches in the Development of Covalent Reversible EGFR Inhibitors

  2019cites this paper
• Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition.

  2018cites this paper
• 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

  2018cites this paper
• The Role Of Cdk8 In Metastatic Growth Of Colon Cancer

  2018cites this paper
• Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation

  2018cites this paper
• Synthesis, Evaluation for Cytotoxicity and Molecular Docking Studies of Benzo[c]furan-Chalcones for Potential to Inhibit Tubulin Polymerization and/or EGFR-Tyrosine Kinase Phosphorylation

  2018cites this paper
• Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential.

  2018cites this paper
• Epidermal growth factor receptor: Structure‐function informing the design of anticancer therapeutics

  2018cites this paper
• New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs

  2018cites this paper
• In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition

  2018cites this paper
• Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.

  2017cites this paper
• Inhibition of epidermal growth factor receptor by ferulic acid and 4-vinylguaiacol in human breast cancer cells

  2017cites this paper
• Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents

  2017cites this paper
• Target Based Design And Synthesis of Heterocycles in the Potential Treatment of Cancer and Opportunistic Infection

  2017cites this paper
• Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation.

  2017cites this paper
• Drug-target interactions that involve the replacement or displacement of magnesium ions.

  2017cites this paper
• A systematic analysis of atomic protein–ligand interactions in the PDB

  2017cites this paper
• Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo

  2017cites this paper
• Investigation of Heck coupling on 6-bromo[2,3-d]thienopyrimidines for construction of new EGFR inhibitor lead structures

  2017cites this paper